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The inflammasome activates caspase-1 and the release of interleukin-1β (IL-1β) and IL-18, and 
several inflammasomes protect against intestinal inflammation and colitis-associated colon cancer 
(CAC) in animal models. The absent in melanoma 2 (AIM2) inflammasome is activated by 
double-stranded DNA, and AIM2 expression is reduced in several types of cancer, but the 
mechanism by which AIM2 restricts tumor growth remains unclear. We found that Aim2-deficient 
mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate 
(AOM/DSS) model of colorectal cancer. Tumor burden was also higher in Aim2−/−/ApcMin/+ than 
in APCMin/+ mice. The effects of AIM2 on CAC were independent of inflammasome activation 
and IL-1β and were primarily mediated by a non–bone marrow source of AIM2. In resting cells, 
AIM2 physically interacted with and limited activation of DNA-dependent protein kinase (DNA-
PK), a PI3K-related family member that promotes Akt phosphorylation, whereas loss of AIM2 
promoted DNA-PK–mediated Akt activation. AIM2 reduced Akt activation and tumor burden in 
colorectal cancer models, while an Akt inhibitor reduced tumor load in Aim2−/− mice. These 
findings suggest that Akt inhibitors could be used to treat AIM2-deficient human cancers.
Colon cancer is one of the leading causes of cancer-related deaths worldwide1. Although 
sporadic tumorigenesis accounts for the majority of these cases, colon cancer can result from 
prolonged inflammatory bowel disease (IBD; e.g., ulcerative colitis and Crohn’s disease). 
IBD pathogenesis is multifaceted and not fully understood, but it is largely associated with 
the chronic infiltration of immune cells, production of inflammatory cytokines and 
activation of the NF-κB family of transcription factors that promote tumorigenesis during 
colitis-associated colon cancer (CAC) (reviewed in ref. 2).
The NLR (nucleotide binding domain and leucine-rich-repeat-containing or NOD-like 
receptor) family of proteins has received much attention in IBD and CAC because of the 
genetic association of NOD2 with Crohn’s disease3,4. In particular, the inflammasome 
complex comprising NLRP3 and its adaptor, apoptosis-associated speck-like protein 
containing a carboxy-terminal CARD (ASC), serves as a protective factor in models of 
colitis and CAC by limiting inflammation and promoting epithelial cell repair primarily 
through production of IL-18 (refs. 5–8). Moreover, loss of IL-18 or the IL-18 receptor 
results in increased susceptibility to CAC tumorigenesis9. Similarly, the NLRP6 
inflammasome also limits colitis and CAC through IL-18 production10 and by altering the 
intestinal microbiome11,12. Other reports imply an alternative role for the NLRP6 and 
NLRC4 inflammasomes in regulating intestinal cell apoptosis13,14, collectively indicating 
that multiple inflammasomes are required for limiting intestinal inflammation and colon 
cancer.
Absent in melanoma 2 (AIM2) is a pyrin-HIN protein that binds cytosolic double-stranded 
DNA and partners with the common inflammasome adaptor ASC to activate the 
inflammasome15,16. Although the role of AIM2 in inflammasome activation is well 
accepted, its role in tumorigenesis is less clear. AIM2 was originally proposed as a tumor 
suppressor gene in melanomas17, and AIM2 mutations are found in human colorectal 
tumors18,19, with reduced AIM2 expression being associated with poor prognosis in 
patients20. Furthermore, AIM2 suppresses cellular proliferation, but the mechanism is 
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unknown21–23. Here, we report a previously unrecognized inflammasome-independent role 
for AIM2 in non–bone marrow cells in restricting tumorigenesis during colitis-associated 
and sporadic colon cancer through suppression of Akt, a master regulator of cellular 
survival.
RESULTS
AIM2 does not affect inflammation and inflammasome activation in colitis models
To assess the role of AIM2 in CAC, we generated Aim2-deficient mice (termed Aim2−/−) on 
the C57BL/6 genetic background (Supplementary Fig. 1a) and verified that Aim2−/− bone 
marrow–derived macrophages (BMDM) failed to produce IL-1β following LPS priming and 
poly(dA:dT) stimulation (Supplementary Fig. 1b). This is identical to what is observed with 
other strains of Aim2−/− mice15,16. Aim2−/− mice did not display alterations in immune cell 
frequencies or numbers of lymphoid organs (Supplementary Fig. 2). To study the role of 
AIM2 in CAC, wild-type, Aim2−/− and Asc−/− mice were intraperitoneally (i.p.) injected 
with azoxymethane (AOM) and then treated with three rounds of 3% dextran sodium sulfate 
(DSS) in drinking water24 (Fig. 1a). This model has been used to show the protective effect 
of multiple inflammasome components, including NLRP3, ASC, NLRC4, NLRP6 and 
caspase-1, against CAC5–7,10,12–14. The mice were assessed for weight loss, survival and 
clinical scores, which included a semiquantitative assessment of stool consistency and rectal 
bleeding7. The inflammasome-deficient Asc−/− mice showed greater weight loss, morbidity 
and clinical scores than Aim2−/− mice (Fig. 1b–d, Supplementary Fig. 3a), as previously 
reported5–7. Increased disease severity in Asc−/− mice was accompanied by increased 
infiltration of inflammatory cells (Fig. 1e) and proinflammatory cytokines in the colon5–7. In 
contrast, disease severity in Aim2−/− mice was indistinguishable from that in wild-type 
controls (Fig. 1b–d). Colon histopathology (blindly scored by a pathologist) revealed no 
difference in the inflammatory infiltrate between Aim2−/− and wild-type colons (Fig. 1e,f). 
Colonic cytokine mRNA expression (Fig. 1g) and cytokine production by colon explants 
(Fig. 1h) were also similar between Aim2−/− and wild-type mice. We next assessed the status 
of inflammasome activation during CAC in wild-type as compared to Aim2−/− mice. Similar 
protein expression of mature caspase-1 p10 subunit (Fig. 1i, Supplementary Fig. 4a) and 
concentrations of IL-1β and IL-18 (Fig. 1j) were detectable in the colons and colon explants, 
respectively, from AOM/DSS-treated wild-type and Aim2−/− mice. In contrast, IL-1β and 
IL-18 production was lower in Asc−/− colons. Because AIM2 associates with ASC to form 
an inflammasome15,16, it was somewhat unexpected that the outcomes for Asc−/− and 
Aim2−/− mice were distinct. However, intact inflammasome activation in Aim2−/− mice 
during CAC is likely due to the presence of other inflammasome-forming sensors, such as 
NLRP3 and NLRP6, which use ASC as an adaptor molecule and may compensate in the 
absence of AIM2 (refs. 5–7,11).
Loss of intestinal barrier integrity promotes intestinal inflammation, and mice deficient in 
inflammasome components display increased intestinal permeability following the induction 
of experimental colitis and CAC5,6,10,13. However, intestinal permeability was not elevated 
in AOM/DSS-treated Aim2−/− mice compared to wild-type mice (Supplementary Fig. 3b), 
consistent with a lack of exaggerated inflammation in these mice. Additionally, weight 
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change and colon length did not differ between Aim2−/− and wild-type mice following 
induction of acute DSS-induced colitis (Supplementary Fig. 5a–c). Moreover, wild-type and 
Aim2−/− mice showed similar morbidity and mortality during an extended time course after 
DSS treatment (Supplementary Fig. 5d–g) and produced similar levels of IL-1β and IL-18 
after chronic DSS exposure (Supplementary Fig. 5h), suggesting that the inflammasome is 
intact in Aim2−/− mice during chronic colitis. As a positive control, IL-1β and IL-18 
production was reduced in the colons of Asc−/− mice during chronic colitis (Supplementary 
Fig. 5h), as previously reported5–7. Finally, we examined another colitis model, which is 
driven by the transfer of naive CD4+ T cells25. The absence of AIM2 in transferred T cells 
did not alter disease severity (Supplementary Fig. 5i–k). Thus, absence of AIM2 did not 
affect the severity of colitis in different animal models.
AIM2 protects against precancerous polyp formation in colitis-associated colon cancer
We next examined the impact of AIM2 on colon polyps, a measurement of precancerous 
growth. High-resolution endoscopy showed that Aim2−/− mice exposed to AOM/DSS had 
greater numbers of polyps compared to wild-type mice (Fig. 2a), and macroscopic polyp 
counts and tumor load assessments indicated that Aim2−/− mice had greater numbers of 
polyps and higher tumor load than Asc−/− and control mice (Fig. 2b,c). Colon histopathology 
from Aim2−/− mice revealed increased crypt dysplasia and hyperplasia compared to wild-
type controls (Fig. 2d,e and Supplementary Fig. 6), even though the mice were similar to 
wild-type animals with respect to inflammatory immune infiltrates in the colon (Fig. 1f). 
Thus, Aim2 deficiency resulted in increased hyperplasia, dysplasia and polyps, without 
attendant increases in inflammation. In contrast, Asc deficiency increased polyp formation to 
a lesser extent than Aim2 deficiency, but did increase inflammation5–7. Because Aim2−/− 
colon explants exhibited a slight, but statistically nonsignificant, increase in IL-1β 
production (Fig. 1j), and IL-1β can promote tumorigenesis (reviewed in ref. 26), we 
generated Aim2−/−/Il1b−/− doubly deficient mice to determine whether IL-1β was 
responsible for the increased CAC in Aim2−/− mice. Consistent with a previous report using 
mice lacking the IL-1β receptor during CAC9, AOM/DSS-treated Il1b−/− mice had numbers 
of colon polyps and tumor loads similar to those of wild-type mice (Fig. 2f). However, 
Aim2−/−/Il1b−/− and Aim2−/− mice did not differ in terms of colon polyp numbers and tumor 
load (Fig. 2f), indicating that IL-1β was not responsible for the increased tumorigenesis in 
Aim2−/− mice. Thus, loss of AIM2 promoted tumorigenesis through a mechanism distinct 
from inflammasome regulation.
A non–bone marrow source of AIM2 protects against precancerous polyp formation
We next determined the cellular source responsible for the enhanced tumorigenesis in the 
absence of AIM2 by generating radiation bone marrow–chimeric mice. Wild-type and 
Aim2−/− mice were exposed to whole-body irradiation (8 Gy) to deplete the hematopoietic-
progenitor compartment. Irradiated recipients were then reconstituted with either wild-type 
or Aim2−/− bone marrow, and CAC was induced using AOM/DSS. Wild-type mice 
reconstituted with Aim2−/− bone marrow (Aim2−/−>WT) exhibited a trend of increased 
tumor size and burden as compared to wild-type control mice (WT>WT), although it did not 
reach statistical significance. An additional statistical analysis by t-test showed that the 
polyp size was significantly larger in Aim2−/−>WT (P = 0.0273) compared to WT>WT 
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mice, but the tumor load was not different (P = 0.073). By contrast, Aim2−/− recipient mice 
reconstituted with wild-type bone marrow (WT>Aim2−/−) were indistinguishable from 
Aim2−/− control mice (Aim2−/−>Aim2−/−) and had increased colon polyp numbers and tumor 
loads as compared to WT>WT controls (Fig. 2g). These results suggest that Aim2 expression 
in radioresistant, non–bone marrow cells was primarily associated with the restriction of 
tumorigenesis during CAC.
Because AIM2 suppressed colon tumorigenesis without affecting inflammasome function or 
limiting inflammation, and AIM2 has been implicated in human colon cancer18–20, we 
hypothesized that AIM2 would perform a similar protective role in a non–colitis-driven 
spontaneous model of colon cancer. To address this hypothesis, we generated Aim2−/− mice 
that contain a heterozygous mutation in the adenomatous polyposis coli (Apc) gene 
(Aim2−/−/ApcMin/+). Mutations in human APC are responsible for the hereditary form of 
colon cancer known as familial adenomatous polyposis (FAP), and mice with this mutation 
develop spontaneous intestinal, and to a lesser extent colorectal, tumors27,28. Aim2−/−/
ApcMin/+ doubly deficient mice had greater numbers of colon tumors and higher tumor loads 
than singly deficient ApcMin/+ mice, the majority of which only had 0 or 1 colon polyp as 
previously described27,28 (Fig. 2h), demonstrating that AIM2 also restricts sporadic colon 
tumorigenesis.
AIM2 inhibits Akt activation to restrict tumorigenesis
To explore the mechanism by which AIM2 impacts tumorigenesis, we explored multiple 
pathways that might be affected in Aim2−/− colon tissue and cells. Loss of AIM2 in 
colorectal cancer lines has been associated with reduced HLA-DRA and HLA-DRB 
expression in vitro29, which could dampen antitumor immunity. However, I-Ab mRNA 
levels in wild-type and Aim2−/− colon polyps or adjacent tissue did not differ 
(Supplementary Fig. 7a). Mitogen-activated protein kinase (MAPK) pathways are major 
regulators of cellular proliferation and apoptosis (reviewed in ref. 30), but no consistent 
differences were detected between wild-type and Aim2−/− mice (Supplementary Fig. 7b). 
The NF-κB family of transcription factors is responsible for initiating inflammation and 
linking inflammation to cancer development (reviewed in ref. 2); however, activation of p65 
and IκBα was not elevated in the colons of AOM/DSS-treated wild-type and Aim2−/− mice 
(Supplementary Fig. 7c). In addition, activated STAT3, which acts in concert with NF-κB to 
promote tumorigenesis (reviewed in ref. 31), was not elevated in Aim2−/− mice 
(Supplementary Fig. 7d).
We next examined the phosphatidylinositol 3-kinase (PI3K)–Akt pathway of cellular 
survival because it is frequently mutated in human colorectal cancer32. Akt activation occurs 
through a series of events that involve the phosphorylation of Akt at threonine 308 (Thr308) 
by the 3-phosphoinositide–dependent protein kinase 1 (PDK1)33 and phosphorylation of 
serine 473 (Ser473) by the mammalian target of rapamycin (mTOR)-rictor complex34. 
Additionally, DNA-dependent protein kinase (DNA-PK) can directly or indirectly 
phosphorylate Akt Ser473 (refs. 35–37). Activated Akt promotes tumorigenesis by 
modulating cell cycle progression, apoptosis and cell motility. By contrast, the tumor 
suppressor phosphatase and tensin homology deleted on chromosome 10 (PTEN) inhibits 
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the actions of PI3K38. Because Akt signaling is important in CAC39, we assessed Akt 
activation in Aim2−/− mice. Similar expression of total Akt (Fig. 3a,b) was found in the 
colons of wild-type, Aim2−/− and Asc−/− mice treated with AOM/DSS, but increased Ser473 
p-Akt and reduced PTEN were found in Aim2−/− colons (Fig. 3a, Supplementary Fig. 4b,f). 
By contrast, slightly reduced levels of p-Akt were found in Asc−/− colons (Fig. 3b, 
Supplementary Fig. 4g). A similar elevation in p-Akt was detected in the colons of 
Aim2−/−/ApcMin/+ as compared to ApcMin/+ control mice (Fig. 3c, Supplementary Fig. 4h), 
demonstrating that AIM2 regulates Akt activity in models of both CAC and sporadic colon 
cancer.
We next assessed whether AIM2 can directly regulate Akt in vitro. AIM2 is widely 
expressed throughout immune tissue and cells17 (Supplementary Fig. 8a). Human intestinal 
tissue17 and colon epithelial cells also express AIM2 (Supplementary Fig. 8b), and AIM2 
mutations are present in colon adenomas and several human colon carcinoma cell lines, 
implying a role for AIM2 in epithelial cells18–20. To examine Akt activation in vitro, we 
treated cells with insulin-like growth factor-1 (IGF-1), which activates PI3K and Akt and is 
elevated in colon cancer40. IGF-1–treated Aim2−/− mouse embryonic fibroblasts (MEFs) had 
increased Ser473 (but not Thr308) p-Akt compared to Aim2+/+ controls (Fig. 3d, 
Supplementary Fig. 4i,j). This difference in p-Akt was not observed in Asc−/− MEFs (Fig. 
3e, Supplementary Fig. 4l), indicating the different roles of AIM2 and ASC in regulating 
Akt activation.
We confirmed that AIM2 regulated Akt activation in colon cancer or colon epithelial cells 
through two approaches. First, the human colon carcinoma cell line HCT-116, which lacks 
functional AIM2 (ref. 19), was reconstituted by transfection with an AIM2-bearing vector 
Akt activation was lower in AIM2-expressing HCT-116 cells than in empty vector–
transfected control cells (Fig. 3f, Supplementary Fig. 4m), indicating that AIM2 reduced Akt 
activation. Second, primary non-transformed colon epithelial organoid cultures were 
generated using a combination of growth factors and signaling molecules in a Matrigel 
system as previously reported (Supplementary Fig. 9)41–43. We assessed Akt activation in 
these three-dimensional organoid cultures isolated from wild-type and Aim2−/− colonic 
crypts and found increased p-Akt in Aim2−/− organoids as compared to wild-type control 
organoids upon IGF-1 stimulation. The basal level of p-Akt was also elevated in Aim2−/− 
organoids, likely due to the required exposure of epidermal growth factor for propagation of 
these primary cells (Fig. 3g, Supplementary Fig. 4n). These results suggest that AIM2 
suppresses Akt activity in non–bone marrow cells, including colonic epithelial cells. In 
contrast to results from colonic epithelial cells, p-Akt did not differ in wild-type and Aim2−/− 
BMDM upon stimulation with LPS or IGF-1 (Supplementary Fig. 10a,b). Thus, AIM2 does 
not affect Akt activation in macrophages, a cell type well-characterized as expressing a 
functional AIM2 inflammasome.
Inhibition of Akt activation in Aim2−/−mice reduces tumor load in vivo
Consistent with the role of Akt in cell proliferation and survival, staining for Ki-67, a marker 
of proliferating cells, was increased in colonic crypts from AOM/DSS-treated Aim2−/− mice 
(Fig. 4a). Proliferation was also increased in Aim2−/− MEFs as compared to Aim+/+ controls 
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(Fig. 4b). Moreover, in Aim2−/− colons, apoptotic caspase-7 cleavage was lower than in 
wild-type colons (Fig. 4c, Supplementary Fig. 4o), and Aim2−/− MEFs had lower apoptotic 
caspase-3 cleavage than controls following staurosporine treatment (Fig. 4d, Supplementary 
Fig. 4p).
To determine whether activated Akt observed in the absence of AIM2 was required for 
increased tumorigenesis in Aim2−/− mice, AOM/DSS-treated wild-type and Aim2−/− mice 
were given a total of six i.p. injections (corresponding to the end of the second and third 
rounds of DSS) of a highly specific Akt inhibitor (API-2) previously described to target 
overactive Akt in cancer cells both in vitro and in vivo44. On day 55 of the AOM/DSS 
model, API-2–treated Aim2−/− mice had decreased colon polyp numbers, smaller polyps and 
reduced tumor loads (Fig. 4e,f) as compared to vehicle-treated Aim2−/− mice following 
AOM/DSS exposure. API-2 treatment did not reduce tumorigenesis in AOM/DSS-treated 
wild-type mice (Fig. 4f), which showed low numbers of colon polyps and little to no 
detectable p-Akt (shown earlier in Fig. 3a). These results suggest activated Akt promotes 
tumorigenesis in Aim2−/− mice, and AIM2 likely restricts tumorigenesis via limiting Akt 
activation.
AIM2 interacts with DNA-PK to regulate Akt activation
Akt signaling is controlled by kinases (including insulin receptor substrate-1/2 (IRS1/2), 
PI3K, 3-phosphoinositide dependent protein kinase-1 (PDK1), mTOR and DNA-PK) and 
phosphatases (including PTEN, protein phosphatase 2A (PP2A) and PH domain leucine-rich 
repeat protein phosphatase (PHLPP)) that are often hyperactive or inactivated, respectively, 
in cancer32. To further explore the mechanism by which AIM2 inhibits Akt activation, we 
examined whether AIM2 interacts with these kinases/phosphatases. The presence of p-Akt 
Ser473, but not Thr308, hyperphosphorylation in Aim2−/− MEFs (Fig. 3d) suggests that 
AIM2 targets an Akt Ser473–specific kinase or phosphatase. Enzymes in the mTOR or 
DNA-PK pathway are known to phosphorylate Akt at Ser473. Because specific antibodies 
against endogenous AIM2 are not available, we overexpressed a 3xFLAG-tagged human 
AIM2 (AIM2-3xFLAG) in HEK293T cells and performed co-immunoprecipitation 
experiments with endogenous Akt-PI3K components. AIM2 did not associate with Akt, 
IGF1 receptor (IGF1R), IRS1, IRS2, PI3K, PDK1, mTOR, ATM, the major PI3K-related 
phosphatases (that is, PTEN, PP2A and PHLPP) or the PTEN-specific ubiquitin ligase 
NEDD4 (Fig. 5a). However, AIM2 did associate with DNA-PK (Fig. 5a), and this was 
confirmed with reciprocal co-immunoprecipitations (Fig. 5b). DNA-PK consists of a 470-
kDa catalytic subunit (DNA-PKcs) and two 73- and 80-kDa DNA-binding subunits (Ku70 
and Ku80)45, and DNA-PK can promote cellular survival via Akt activation35,37. Elevated 
DNA-PK activity and expression has been reported in colorectal tumors46, and DNA-PK 
promotes c-Myc oncoprotein stability47. As both AIM2 and DNA-PK bind DNA, their 
interaction could be a consequence of nonspecific DNA bridging. To address this 
possibility, immunoprecipitates were treated with the DNA-intercalating agent ethidium 
bromide (EtBr) to disrupt DNA interactions that could promote indirect associations. The 
AIM2–DNA-PKcs association was maintained in the presence of EtBr (Fig. 5c), indicating 
that this association is not an artifact of their binding to DNA.
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The AIM2-DNA-PKcs interaction was detected in resting cells, but lost upon IGF-1 
stimulation (Fig. 5a,b), suggesting that the interaction occurred in the resting state but these 
proteins dissociated from each other upon cellular activation, allowing DNA-PKcs to 
promote Akt activation. To address this possibility, we tested whether AIM2 could directly 
prevent DNA-PK activation by using AIM2-complemented HCT-116 cells treated with 
bleocin, which induces potent DNA-PK phosphorylation45. Indeed, AIM2 overexpression 
decreased phosphorylation of DNA-PK (p-DNA-PK; Fig. 5d, Supplementary Fig. 4q), 
demonstrating that AIM2 can limit DNA-PK activation. To assess the link between AIM2, 
DNA-PK and Akt activation, we tested two highly-specific DNA-PKcs inhibitors, NU7026 
and NU7441 (ref. 48), in Aim2−/− and control cells. Akt Ser473 phosphorylation was higher 
in IGF-1-treated Aim2−/− cells as compared to IGF-1-treated wild-type controls, but this 
difference was not observed with either NU7026 or NU7441 treatment (Fig. 5e, 
Supplementary Fig. 4r). Additionally, p-Akt activation is known to have prosurvival effects. 
Reduced apoptosis and increased viability in Aim2−/− cells as compared to wild-type cells 
was reversed by DNA-PK inhibitors (Fig. 5f, Supplementary Fig. 4s and Fig. 5g). These 
results suggest DNA-PK is required for elevated Akt activation in Aim2−/− cells.
DISCUSSION
The innate immune DNA sensor AIM2 has been implicated as a potential tumor suppressor, 
although the mechanism for this effect remained unclear. Here, we assessed the role of the 
AIM2 inflammasome in the regulation of CAC, but instead found that AIM2 attenuates 
tumorigenesis through a mechanism independent of inflammasome activation and 
inflammation. In colon epithelial cells, AIM2 limits the activation of Akt, a master regulator 
of cellular survival often overexpressed in multiple human cancers. AIM2 in resting cells 
physically associates with and limits activation of DNA-PK, a PI3K-related family member 
that promotes Akt. Conversely, loss of AIM2 promotes DNA-PK–mediated Akt 
hyperactivation, thereby promoting proliferation and reducing apoptosis, two hallmarks of 
cancer development.
AIM2 mutations are found in human tumors18,19, reduced AIM2 expression has been 
associated with poor prognosis in patients20 and AIM2 suppresses proliferation21–23. Our 
findings indicate that loss of AIM2 results in activation of Akt, and suppression of Akt can 
reduce tumorigenesis in Aim2-deficeint animals. Thus, pharmacological targeting of Akt 
may be beneficial in individuals with AIM2-deficent tumors. This work implicates AIM2 as 
having a previously unrecognized role in the dual regulation of innate immune networks and 
signaling pathways that are critical to cellular survival and tumorigenesis. Although this 
study focused on colorectal cancer models, loss or mutations in APC in mice are also 
associated with intestinal tumorigenesis27,28. Furthermore, AIM2 is implicated in human 
melanoma17, and thus further work is needed to investigate whether targeting Akt is 
beneficial in other cancers associated with AIM2 deficiency.
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All animal protocols were approved by the University of North Carolina Chapel Hill (UNC) 
Institutional Animal Care and Use Committee (IACUC) in accordance with the US National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Animal numbers 
were empirically determined to optimize numbers necessary for statistical significance based 
on our previous reports utilizing these disease models7 (minimum of 4–7 animals/group for 
each type of analysis) while adhering to IACUC polices on maximum numbers of animals 
used in research. These numbers were also determined based on breeding efficiency, animal 
housing space and handling limitations. No randomization method was used due to the 
experimental setup, ad libitum administration of DSS and littermate groups. All experiments 
were performed under specific pathogen-free conditions using 6- to 8-week-old male mice. 
Animals that exhibited health concerns not related to the study conditions (for example, 
fight wounds and dermatitis) were excluded from the analysis. Wild-type (WT) C57BL/6 
mice were obtained from the Jackson Laboratories (Bar Harbor, ME) and maintained at 
UNC Chapel Hill for more than 9 generations. Asc−/− mice on the C57BL/6 background 
have been described elsewhere49.
The Aim2 knockout (Aim2−/−) mice were generated by Ingenious Targeting Laboratory 
(Ronkonkoma, NY) on the C57BL/6 background via targeted replacement of the Aim2 
coding region with a neomycin resistance gene through homologous recombination 
(depicted in Supplementary Fig. 1a). Primer sequences used for PCR-based Aim2−/− mouse 
genotyping are as follows: neomycin (KO) forward, 
GGAACTTCGCTAGACTAGTACGCGTG; neomycin (KO) reverse, 
CAACATTGTACAGATTGAGCAGG; Aim2 (WT) forward, 
GATGGAGAGTGAGTACCGGGAAATGCTGTT; and Aim2 (WT) reverse, 
TCTGCAAGTAGATTGGAGACAGACTCTGGTGA, resulting in a 450-bp band for the 
wild type and a 250-bp band for the targeted Aim2 knockout when PCR analysis is 
performed on the genomic DNA (Supplementary Fig. 1a).
The ApcMin/+ mice on the C57BL/6 background were purchased from Jackson Laboratories 
(Bar Harbor, ME) and maintained at UNC Chapel Hill. Aim2−/− mice were crossed with 
ApcMin/+ mice to generate Aim2−/−/ApcMin/+ mice.
Experimental colitis and colitis-associated colon cancer
For induction of colitis, mice were given 4–5% dextran sulfate sodium salt (DSS) (MP 
Biomedical, LLC) dissolved in drinking water for 5 consecutive days followed by regular 
drinking water for 6 or 10 days (Supplementary Fig. 5a,d)24. To induce colitis-associated 
colon cancer (CAC), animals were given a single i.p. injection of the mutagen 
azoxymethane (AOM, Sigma-Aldrich) (10 mg/kg body weight) in combination with three 
cycles of 3% DSS in drinking water for 5 days followed by regular drinking water for 14 
days24 (Fig. 1a). Animals were killed following completion of either model or when 
moribund.
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Animals were blindly monitored for weight loss daily during DSS treatment and once every 
2 days during regular water administration to assess disease progression. In addition, clinical 
score assessments were blindly performed after administration of each round of DSS to 
evaluate stool consistency, rectal bleeding and stool blood measurements using Hemoccult 
Immunochemical Fecal Occult (Beckman Coulter) as previously described7.
For induction of chronic T cell–mediated colitis, spleens from healthy wild-type and 
Aim2−/− mice were isolated, gently dissociated and passed through a 70-µm cell strainer to 
generate single-cell suspension, and red blood cells were lysed using ACK buffer. Naive 
CD4+ T cells were purified by negative selection using the MACS Naïve CD4+ T Cell 
Isolation Kit (Miltenyl Biotech) and i.p. injected at 5 × 105 cells/mouse into recipient 8- to 
10-week-old T and B cell–deficient Rag1−/− mice as previously described50. Animals were 
weighed weekly and killed at 8 weeks post-T cell transfer. Spleens were removed, total 
lymphocytes were isolated and the expansion of colitogenic CD4+T cells (and the absence of 
CD8+ T cells) was verified by flow cytometry.
Macroscopic polyp assessment
Colon tumorigenesis was visualized in situ using mini-endoscopy7. Animals were fasted 
overnight before endoscopy to minimize fecal obstruction during visualization, and a trained 
gastroenterologist (M.M.) performed endoscopy on the animals under oxygen-regulated 
isoflurane sedation on day 48 of the AOM/DSS model using a Coloview system (Karl Storz 
Veterinary Endoscope). The trained gastroenterologist was blinded to the genotype and 
experimental condition of the animals.
Upon completion of the AOM/DSS model of CAC, the mice were killed and colons were 
removed, flushed with PBS and opened longitudinally for visual polyp count by a trained 
investigator blinded to the genotype and experimental condition of the animals7. Tumor 
loads were determined as the sum of the diameters of all colon tumors present per mouse24. 
For spontaneous colon cancer assessment, ApcMin/+ and Aim2−/−/ApcMin/+ mice were killed 
at 12 weeks of age and colons were processed and assessed for macroscopic polyps as 
described above.
Assessment of intestinal permeability
AOM/DSS-treated wild-type and Aim2−/− mice were fasted for 3.5 h and fed FITC-dextran 
(MW 4,000, Sigma-Aldrich) at 60 mg/100 g body weight via oral gavage. Animals were 
killed 3.5 h later, and blood was removed via heart puncture. Fluorescence of serum FITC-
dextran was measured using a plate reader at excitation 520 and emission 490 nm.
Generation of radiation bone marrow chimeras
Radiation bone marrow chimeric mice were generated as previously described7. Briefly, 10- 
to 12-week-old wild-type CD45.1+ and Aim2−/− CD45.2+ mice were lethally irradiated (8 
Gy) and i.v. injected with 107 bone marrow cells isolated from either wild-type CD45+ or 
Aim2−/− CD45.2+ mice 24 h post-irradiation. Recipient mice were given 2 mg/ml neomycin 
in drinking water for 14 days, and bone marrow was allowed to reconstitute an additional 56 
days before administration of AOM/DSS. The recipient mice were bled at 49 days post-bone 
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marrow transplant, and the levels of peripheral blood lymphocyte CD45.1 verses CD45.2 
was measured in order to determine the bone marrow reconstitution efficiency, which was 
89–98% (data not shown).
Inhibition of Akt during colitis-associated colon cancer
Wild-type and Aim2−/− mice were given an i.p. injection of API-2 (1 mg/kg body weight in 
10% DMSO) or 10% DMSO vehicle control on days 22, 25, 28, 41, 44 and 47 of the 
AOM/DSS model (3 injections during the second and third rounds of 3% DSS 
administration). Animals were killed at day 55 post-AOM/DSS, and macroscopic polyps 
were visualized as described above.
Histopathology
For assessment of tissue pathology, colons were affixed to cards in Swiss-roll fashion, fixed 
in 10% neutral-buffered formalin and routinely paraffin embedded and processed. 
Hematoxylin and eosin (H&E) staining was performed on 5-micron-thick colon sections, 
and inflammation, hyperplasia and dysplasia were scored by a Board-certified veterinary 
pathologist (A.B.R.) blinded to the genotype and experimental condition of each animal as 
previously described7. Additional sections were stained by immunohistochemistry for the 
proliferation marker Ki-67 (Cell Signaling Technology) and counterstained using 3,3′-
diaminobenzidine (DAB) followed by hematoxylin counterstain. The percentage of Ki-67+ 
nuclei was calculated using ImageJ software.
qPCR
Inflammatory cytokine expression was assessed during CAC by washing colons with PBS 
and homogenizing the distal-most section for total RNA isolation using RNeasy Blood & 
Tissue kit (Qiagen), according to the manufacturer’s instructions. cDNA was generated 
using Superscript III (Invitrogen) according to the manufacturer’s instructions, and real-time 
PCR was performed for mouse Tnfa (Mm00443258), Il6 (Mm00446190), Il1b 
(Mm01336189), Il17a (Mm01189488), Ptgs2 (Mm00478374) and Il10 (Mm00439614) gene 
expression using mouse Taqman Gene Expression Assays (Applied Biosystems) and for I-
Ab using SYBR green master mix (primer sequence: Reverse, 
CTGTCGTAGCGCACGTACT; Forward, GGCGAGTGCTACTTCACCA. The PCR 
results were normalized to Gapdh expression and were quantified by the ΔΔCT method.
Colon explant cultures for inflammatory cytokine production
Colon inflammatory cytokine secretion was assessed during CAC by flushing colons from 
AOM/DSS-treated mice repeatedly with PBS containing penicillin/streptomycin, and the 
distal-most 1-cm2 colon sections were cultured for 15 h in RPMI media containing 2× 
penicillin/streptomycin. Supernatants from these cultures were removed, cleared of debris 
by centrifugation and assessed for mouse IL-6, TNF, IFN-γ and IL-10 by Bio-Plex cytokine 
assay (Bio-Rad) and IL-1β (BD Biosciences) and IL-18 (eBioscience) by ELISA.
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Protein expression of caspase-1, caspase-7, STAT3, MAPK, NF-κB and PI3K pathway 
members was assessed during CAC by homogenizing the distal-most section of the colon in 
1% RIPA buffer (Boston Bioproducts) containing Complete Protease Inhibitor cocktail 
(Roche) and phosphatase inhibitor cocktail (phosSTOP, Roche) cocktail. Cell lysates were 
cleared by centrifugation, and the protein concentration was determined by BCA protein 
assay (ThermoScientific). A total of 30 µg of protein was mixed in SDS loading dye 
(Novex) containing 20 mg/ml DTT reducing agent, boiled for 5 min, separated by SDS-
PAGE using 4–12% Bis-Tris gels (Novex) and wet transferred to nitrocellulose membranes 
(Roche). Nitrocellulose membranes were blocked for 1 h with 5% non-fat milk and 
incubated overnight with primary antibodies, washed 5 times with TBS-T and incubated for 
1–2 h at room temperature with the appropriate goat anti-rabbit or bovine anti-goat HRP-
conjugated secondary antibodies (Santa Cruz Biotechnology and Sigma-Aldrich).
In vitro cell lines and primary cells were lysed in 1% RIPA or 1% NP-40 containing 
protease and phosphatase inhibitors (Roche), and then cellular lysates were cleared of 
cellular debris by centrifugation and were subjected to SDS-PAGE and western blotting as 
described above.
The cell lysates were immunoblotted using the following primary antibodies: anti-IL-1β (cat. 
no. AF401-NA) (R&D Systems); anti-PTEN (cat. no. 611500) (BD Bioscience); anti-
caspase-1 (M-20) (cat. no. sc-514), anti-ERK1/2 (C-16) (cat. no. sc-093), anti-PHLPPL 
(T-17) (cat. no. sc-137663), and actin-HRP (C-11) (cat. no. sc-1615), anti-IRS1 (C-20) (cat. 
no. sc-559), anti-JNK (C-17) (cat. no. sc-474) (Santa Cruz Biotechnology); anti-pERK1/2 
(T202/Y204) (cat. no. 4370), anti-p38 (cat. no. 9212), anti-pp38 (T180/Y182) (cat. no. 
9216), anti-pJNK (T183/Y185) (cat. no. 9251), anti-p65 (D14E12), anti-pp65 (S536) (cat. 
no. 93H1), anti-IκBα (44D4) (cat. no. 4812), anti-pIκBα (S32) (14D4) (cat. no. 2859), anti-
STAT3 (cat. no. 79D7), anti-pSTAT3 (Y705) (cat. no. 9131), anti-IGFR (D23H3) (cat. no. 
9750), anti-IRS2 (L1326) (cat. no. 3089), anti-PI3K p85 (19H8) (cat. no. 4257), anti-mTOR 
(cat. no. 2972), anti-pmTOR (S2448) (cat. no. 2971), anti-pPDK1(cat. no. 3062), anti-pAkt 
(Thr308) (cat. no. 2965), anti-pAkt (Ser473) (cat. no. 4060), anti-Akt (cat. no. 9272), anti-
caspase-3 (cat. no. 9662), anti-cleaved caspase-7 (Asp198) (cat. no. D6H1), anti-PP2A 
(81G5) (cat. no. 2041), anti-NEDD4 (cat. no. 2740) and anti-ATM (D2E2) (cat. no. 2873) 
(Cell Signaling Technology); anti-Flag-HRP (M2) (cat. no. A8592); anti-Flag (cat. no. 
F7425), anti-DNA-PKcs (cat. no. SAB4502385), (Sigma-Aldrich); and anti-pDNA-PK 
(S2056) (cat. no. ab18192) (Abcam). All primary antibodies were used at 1:1,000. 
Secondary antibodies include the following: goat anti-rabbit HRP (111-035-144), goat anti-
mouse HRP (115-035-146) and donkey anti-goat HRP (805-035-180); all secondary 
antibodies were used at 1:40,000. Protein bands were quantified by densitometric analysis 
using ImageJ software.
Primary cell generation
Mouse embryonic fibroblasts (MEFs) were generated by mating an Aim2 heterozygous 
(Aim2+/−) breeder pair or an Asc heterozygous (Asc+/−) breeder pair and isolating the 
embryonic day 13.5 (E13.5) embryos from the female. The genotype of the Aim2+/+ and 
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Aim2−/− littermates (or Asc+/+ and Asc−/− littermates) were confirmed by PCR, and the head 
and internal organs were removed from the embryos. The remaining tissue was minced, 
digested with 0.05% trypsin EDTA (Gibco) in the presence of DNase (Sigma-Aldrich) and 
the resulting cells were plated to confluency in Dulbecco’s Modified Eagle Medium 
(DMEM, Gibco) containing 10% FBS (Sigma-Aldrich), penicillin/streptomycin, 4.5 g/L D-
glucose, 4mM L-glutamine and 110 mg/L sodium pyruvate. A total of three independently 
generated Aim2+/+ and Aim2−/− littermate MEFs were used for this study, and all MEFs 
were non-immortalized and below passage 6.
Bone marrow–derived macrophages were generated by flushing bone marrow from the 
femurs and tibias of wild-type, Asc−/− and Aim2−/− mice. Red blood cells were lysed using 
ACK buffer, and the remaining bone marrow cells were differentiated into macrophages by 
culturing for 6–7 days in DMEM with GM-CSF-containing L929-conditioned media.
Highly proliferative 3D spheroids (termed organoids) of colonic epithelial cells were 
cultured in vitro according to previous publications41–43. Briefly, colon crypts were isolated 
from mice by soaking the excised colon in a chelating buffer (2.0 mM EDTA and 0.5 mM 
DTT) for 75 min followed by vigorous shaking. A total of 50,000 crypts were suspended in 
300 µL of cold Matrigel (Corning Life Sciences) on ice, and the 15 µL of the suspension was 
added to the center of each well of a 24-well plate. The plate was inverted and incubated at 
37 °C for 10 min to solidify Matrigel. A total of 0.5 ml of advanced DMEM/F12 medium 
containing Wnt-3A-containing L929-conditioned medium, R-spondin 2-containing 
HEK293-conditioned medium (a kind gift from J. Whitsett at Cincinnati Children’s 
Hospital), Noggin-containing HEK293-conditioned medium (provided by N.L.A) 
(volumetric ratio of 3:1:1:1), 50 ng/ml EGF (Biovision), 10 µM Y27632 ROCK inhibitor 
(LC Laboratories), 1mM N-acetyl-L-cysteine (Sigma-Aldrich), GlutaMAX, 10 mM HEPES, 
penicillin/streptomycin and 5 µg/ml gentamicin. The medium was changed every 48 h, and 
the organoids were passaged every 5 days at a 1:5 split ratio. Medium was removed from the 
well, and trypsin-EDTA (0.05%) was added. After incubation at 37 °C for 5 min, organoids 
were dissociated into small fragments by pipetting. Cells were then washed, embedded in 
fresh Matrigel and plated into 24-well plate. Day 5 differentiated organoids were used in 
experiments.
Cell culture
The human colorectal carcinoma HCT-116 cell line (American Type Culture Collection 
(ATCC)# CCL-247) was cultured in McCoy’s 5A media with 10% FBS and penicillin 
streptomycin. The embryonic kidney epithelial cell line HEK293T (ATCC# 3216) was 
cultured in DMEM containing 10% FBS (Sigma-Aldrich), penicillin/streptomycin, 4.5 g/L 
D-glucose, 4 mM L-glutamine and 110 mg/L sodium pyruvate. All cell lines were 
maintained at 37 °C with 5% CO2. Cells were routinely checked for mycoplasma by the 
Lineberger Cancer Center Tissue Culture Facility at UNC Chapel Hill and were 
authenticated by ATCC prior to purchase.
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AIM2-Flag and DNA-PK co-immunoprecipitation experiments were carried out in 293T 
cells that were transfected with 1 µg/ml of AIM2-Flag or empty vector (pCIG2-IRES-
PURO) using Lipofectamine reagent according to manufacturer’s instructions. Cells were 
stimulated as indicated at 48 h post-transfection and lysed in NP-40 lysis buffer containing 
Complete protease inhibitor cocktail (Roche). Cell lysates were centrifuged to remove 
insoluble material, pre-cleared with 10% zysorbin (Novex) and incubated overnight at 4°C 
with rotation with either anti-Flag antibody (a kind gift from M.A. Accavitti-Loper at 
University of Alabama, Birmingham) or anti-DNA-PKcs (Sigma-Aldrich). Ethidium 
bromide was added during the overnight antibody incubation at a concentration of 50 µg/ml 
where indicated. The lysates were incubated with Protein A/G Ultra-link resin (Thermo 
Scientific) for 2 h at 4 °C with rotation followed by 4 washes in NP-40 lysis buffer. For anti-
Flag immunoprecipitations, protein was eluted using 3xFlag peptide (Sigma-Aldrich). For 
anti-DNA-PKcs immunoprecipitations, protein was eluted by boiling beads in SDS loading 
dye (Novex) containing 20 mg/ml DTT.
AIM2 constructs
pCIG2-PURO-hAIM2-3x-Flag was generated using traditional cloning methods. Briefly: 
two primers encoding a glycine linker and a 3x-Flag tag 
(GGGGDYKDDDDKGADYKDDDDKEFDYKDDDDK) were annealed and extended to 




CCTTGTAGTCTGCCCCTTTATC), which served as the reverse primer for the PCR 
amplification with an AIM2 forward primer 
(ggggGCTAGCACCATGGAGAGTAAATACAAGGAGATACTCTTGCTAACAGGC). 
The 3x-Flag tagged AIM2 amplicon was cloned into the NheI/BamHI site of pCIG2-IRES-
PURO, a variant of pCIG2-IRES-eGFP51. TRC Lentiviral Human AIM2 shRNA constructs 
were purchased form Open Biosystems as bacterial glycerol stocks. Plasmids were purified 
using the Nucleobond Xtra Maxi Plus Kit (Macherey Nagel). AIM2-Flag expressing 
lentiviruses were generated in 293FT cells as previously described51.
AIM2 inflammasome activation
Wild-type and Aim2−/− macrophages were plated overnight, primed with 500 µg/ml LPS 
(Peprotech) for 3 h and stimulated for 6 h with 1 µg/ml poly(dA:dT) (Invivogen) combined 
with Lipofectamine 2000 transfection reagent (Invitrogen), according to the manufacturer’s 
instructions, for IL-1β assessment as previously described15.
PI3K activation
MEFs and macrophages were plated overnight and stimulated with 100 ng/ml of insulin-like 
growth factor-1 (IGF-1, R&D Systems) or 500 µg/ml lipopolysaccharide (LPS) to assess Akt 
activation by western blot. HCT-116 cells were plated overnight and transfected with 1 
µg/ml of EV or AIM2-Flag using Lipofectamine 2000 according to the manufacturer’s 
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instructions. HCT-116 cells were stimulated with IGF-1 (100 ng/ml) 48 h post-transfection. 
Day 5–differentiated primary organoids were generated as described above and stimulated 
with 100 ng/ml IGF-1 for 20 min.
Cell death assay
Aim2+/+ and Aim2−/− MEFs were plated overnight and stimulated with 0.5 µM staurosporine 
(Sigma-Aldrich) for the indicated times. Cells were washed and processed for cleaved 
caspase-3 expression by western blot analysis.
DNA-PKcs ihibitors
When indicated, MEFs were pre-treated for 30 min or 1 h with the indicated concentration 
of the DNA-PKcs inhibitors NU7026 (Cayman Chemical) or NU7441 (Tocris), or cultured 
with a single dose of NU7026 for proliferation assays.
Flow cytometry
Spleen, thymus and inguinal lymph nodes were isolated from naive Aim2+/+, Aim2+/− and 
Aim2−/− animals; tissue was gently dissociated and passed through a 70-µm cell strainer to 
generate single cell suspension; and red blood cells were lysed using ACK buffer. Cells 
were counted and stained using the following antibodies: anti-CD11b-FITC (cat. no. 
11-0112, used at 1:200), anti-CD4-PerCpCy5.5 (cat. no. 45-0042, used at 1:80), anti-CD8-
eFluor 450 (cat. no. 48-0083, used at 1:80), anti-CD11c-APC (cat. no. 17-0114, used at 
1:80), anti-TCRβ-Alexa 700 (cat. no. 47-5961, used at 1:80), anti-F480-PE (cat. no. 
12-4801, used at 1:80), anti-NK1.1-PECy7 (cat. no. 25-5941, used at 1:80) (eBioscience) 
and anti-B220-APC Cy7 (cat. no. 565371, used at 1:200) (BD Biosciences). Peripheral 
blood lymphocytes isolated from radiation bone marrow chimeric mice were stained with 
anti-CD45.1-PE (BD Biosciences, cat. no. 553776, used at 1:1,000) and anti-CD45.2-V500 
(BD Biosciences, cat. no. 562130, used at 1:1,000). Flow cytometry was performed using an 
LSRII (BD Biosciences), and the resulting data were analyzed using FlowJo (TreeStar).
Statistical analysis
All results are presented as the mean ± s.e.m. (SEM). Significance between two groups was 
assessed by the Student’s two-tailed t-test. The non-parametric Mann-Whitney U-test was 
used to assess significance between two means of data sets lacking a normal distribution and 
having a small sample size. Data sets consisting of more than 2 groups were analyzed by 
analysis of variance (ANOVA) with Tukey-Kramer HSD post test for multiple comparisons 
if significance was determined. The product limit method of Kaplan and Meier was used for 
generating the survival curves, which were compared by using the log-rank test. A P value 
that was less than 0.05 was considered statistically significant for all data sets. All statistical 
analysis was performed using GraphPad Prism software. Samples that were greater than 3 
s.d. from the mean were excluded as outliers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AIM2 is distinct from ASC during colitis-associated colon cancer. (a) Induction procedure 
for the AOM/DSS model of CAC. (b–d) Weight loss (b), % survival (d, days) (c) and 
average clinical scores (d) in Aim2−/− (n = 25), Asc−/− (n = 11) and wild-type (n = 30) mice 
following induction of CAC using AOM/DSS. Mock wild-type animals (n = 10) received a 
single i.p. injection of AOM and were given regular drinking water instead of DSS. Error 
bars, s.e.m. (e) H&E staining of colons from AOM/DSS-treated wild-type, Aim2−/− and 
Asc−/− mice and (f) semiquantitative scoring of inflammation in colons from AOM/DSS-
treated wild-type and Aim2−/− mice (n = 6 for WT AOM/Mock and Aim2−/− AOM/DSS, and 
n = 5 for WT AOM/DSS and Aim2−/− AOM/Mock). Images were taken at 200× 
magnification; scale bars, 100 µm. (g) Inflammatory cytokine mRNA (AU, arbitrary units) 
(n = 3 for WT AOM/Mock and Aim2−/− AOM/Mock, and n = 6 for WT AOM/DSS and 
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Aim2−/− AOM/DSS) and (h) protein expression in wild-type and Aim2−/− colons (n = 5 for 
WT AOM/Mock and Aim2−/− AOM/Mock, n = 10 for WT AOM/DSS and n = 8 for Aim2−/− 
AOM/DSS). (i) Caspase-1 activation in wild-type and Aim2−/− colons and (j) IL-1β and 
IL-18 production in wild-type, Aim2−/− and Asc−/− colons (n = 5 for WT AOM/Mock, 
Aim2−/− AOM/Mock and Asc−/− AOM/Mock, and n = 10 for WT AOM/DSS, n = 8 for 
Aim2−/− AOM/DSS and n = 5 for Asc−/− AOM/DSS). Error bars, s.e.m. *P < 0.05, **P < 
0.01, ***P < 0.001; b,d,j, one-way ANOVA (Tukey's multiple-comparisons test); c, log-
rank test.
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AIM2 protects against colon tumorigenesis. (a,b) Mini-endoscopy (a) and representative 
images (b) of colons from AOM/DSS-treated wild-type (n = 5), Asc−/− (n = 3) and Aim2−/− 
mice (n = 5). (c) Macroscopic polyp counts, average polyp size per mouse and tumor load (n 
= 21 for WT, n = 18 for Aim2−/− and n = 10 for Asc−/−). (d,e) Semiquantitative scoring of 
colon hyperplasia (d) and dysplasia (e) in AOM/DSS-treated wild-type and Aim2−/− mice (n 
= 6 for WT AOM/Mock and Aim2−/− AOM/DSS, and n = 5 for WT AOM/DSS and Aim2−/− 
AOM/Mock). (f) Colon polyp counts, average polyp size per mouse and tumor load in 
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AOM/DSS-treated wild-type, Aim2−/−, Il1b−/− and Aim2−/−/Il1b−/− mice, with representative 
images of colons in the right panel (n = 5 for wild-type, Aim2−/− and Il1b−/−, and n = 4 for 
Aim2−/−/Il1b−/−). (g) Colon polyp counts, average polyp size per mouse and tumor load in 
AOM/DSS-treated wild-type and Aim2−/− radiation bone marrow chimeras, with 
representative images of colons in the right panel (n = 4 for WT>WT, n = 5 for 
WT>Aim2−/− and n = 7 for Aim2−/−>WT and Aim2−/−>Aim2−/−). (h) Colon polyp counts, 
average polyp size per mouse and tumor load in ApcMin/+ and Aim2−/−/ApcMin/+ mice 
representative images of colons in the right panel (n = 6 mice/group). Each symbol 
represents one animal. Error bars, s.e.m. ns, not significant; *P < 0.05, **P < 0.01, ***P < 
0.001; c,g, one-way ANOVA (Tukey's multiple-comparisons test); d,e,f,h, unpaired t-test.
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AIM2 negatively regulates Akt activity in vitro and in vivo. (a,b) Western blot analyses of 
PI3K pathway members in the colons of AOM/DSS-treated mice (representative of n = 6 
mice/group). (c) Western blot analyses of Akt phosphorylation in colon homogenates from 
12-week-old ApcMin/+ and Aim2−/−/ApcMin/+ mice (representative of n = 6 mice/group). (d–
g) Western blot analyses of Akt phosphorylation in IGF-1–simulated MEFs from Aim2+/+ 
and Aim2−/− littermates (d), Asc+/+ and Asc−/− littermates (e), AIM2–3xFlag- or EV-
transfected HCT-116 cells (f), and wild-type and Aim2−/− organoids (g). Actin (β-actin) and 
total Akt were used as loading controls. Results are representative of 1 of 3 experiments.
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AIM2 restricts cell proliferation and promotes apoptosis. (a) Colon Ki-67 staining in AOM/
DSS-treated wild-type and Aim2−/− mice (n = 6 for WT AOM/Mock and Aim2−/− AOM/
DSS, and n = 5 for WT AOM/DSS and Aim2−/− AOM/Mock). 200× magnification; scale 
bars, 100 µm; error bars, s.e.m. (b) Cell numbers of Aim2+/+ and Aim2−/− MEFs (d, days). 
Error bars, s.e.m., from triplicate samples per group. (c) Western blot analyses of activated 
caspase-7 and procaspase-7 in colons from AOM/DSS-treated wild-type and Aim2−/− mice 
(n = 6 mice/group). (d) Western blot analyses of activated caspase-3 and procaspase-3 in 
staurosporine (Staur)-treated Aim2+/+ and Aim2−/− MEFs (h, hours). Results are 
representative of 1 of 3 experiments. (e) Representative images of colons from DMSO- or 
Akt inhibitor (API-2)-treated Aim2−/− mice. (f) Number of macroscopic colon polyps, 
average polyp size and tumor load in API-2-treated Aim2−/− mice. Each symbol represents 
one animal. Error bars denote standard error. ns, not significant. *P < 0.05, **P < 0.01, 
***P < 0.001. a,b, unpaired t-test; f, Mann-Whitney U-test (due to the non-normal 
distribution of the data sets and small sample size).
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AIM2 associates with DNA-PK and restricts its activity and Akt phosphorylation. (a) 
Immunoprecipitation of AIM2 and immunoblots of PI3K members and (b) reciprocal 
immunoprecipitation of DNA-PKcs and immunoblot of AIM2 in AIM2-Flag (Fg)- or empty 
vector (EV)-expressing HEK293T cells treated with IGF-1 (IGF) (c) Co-
immunoprecipitation of DNA-PKcs and AIM2 in the presence of ethidium bromide (EtBr) 
in HEK293T cells. (d) Western blot analysis of phosphorylated DNA-PK (p-DNA-PK) in 
bleocin-treated AIM2-expressing HCT-116 cells. (e) Western blot analysis of p-Akt in 10 
µM NU7026- or NU7441-treated Aim2+/+ and Aim2−/− MEFs. (f) Western blot analysis of 
activated caspase-3 in staurosporine (Stauro)-treated Aim2+/+ and Aim2−/− MEFs treated 
with NU7026 (5 µM; h, hours). (g) Cell number of Aim2+/+ and Aim2−/− MEFs cultured with 
1 µM NU7026 (d, days). Error bars, s.e.m., from triplicate samples per group. Results are 
representative of 1 of 3 independent experiments (a,b,c,d,e,g) and representative of 1 of 2 
independent experiments (f). **P < 0.01, ***P < 0.001. One-way ANOVA (Tukey's 
multiple-comparisons test).
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